ProCE Banner Activity

Expert Strategies to Optimize the Treatment of Patients With Squamous NSCLC

Multimedia
In this on-demand Webcast from the 2017 CCO squamous NSCLC live meeting series, Paul K. Paik, MD, provides expert perspective on the optimal treatment of patients with advanced squamous NSCLC including discussion of the most recent clinical data and emerging therapeutic strategies.

Released: December 18, 2017

Expiration: December 17, 2018

No longer available for credit.

Share

Faculty

Edward S. Kim

Edward S. Kim, MD

Chief, Section of Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Mark A. Socinski

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Paul K. Paik

Paul K. Paik, MD

Assistant Attending
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Boehringer Ingelheim

Celgene

Lilly

Learning Objectives

  • Plan individualized treatment strategies for patients with newly diagnosed squamous NSCLC
  • Incorporate current evidence-based treatment recommendations into the care of patients with metastatic squamous NSCLC that has progressed on or after frontline therapy
  • Discuss promising investigational agents and emerging therapeutic strategies with patients with squamous NSCLC based on an understanding of available clinical data and ongoing clinical trials

Program Director Disclosure

Program Director

Edward S. Kim, MD

Chief, Section of Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Edward S. Kim, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Celgene, and Lilly.

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Mark A. Socinski, MD, has disclosed that he has received fees for non-CME/CE services received directly from a commercial interest or their agents (eg, speaker bureaus) from Bristol-Myers Squibb, Celgene, Genentech, and Lilly and funds for research support from Celgene, Genentech, and Pfizer.

Faculty Disclosure

Primary Author

Paul K. Paik, MD

Assistant Attending
Clinical Director, Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Paul K. Paik, MD, has disclosed that he has received consulting fees from Celgene and Lilly and funds for research support from Celgene.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.